Diligence memo · auto-generated · as of July 2, 2026
Theraclion
Theraclion looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Theraclion operates in Biotechnology, based in MALAKOFF.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Theraclion has raised $250K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $250K on 2015-06-19.
Most recent recorded round closed around 2015-06-19.
Valuation (modeled)modeled
Provath models Theraclion at approximately $14M (range $133K–$157M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.87× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era. Within the normal band (87% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 11.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 6% of Biotechnology peers (4293 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.